S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
NASDAQ:EVFM

Evofem Biosciences Stock Forecast, Price & News

$0.44
-0.01 (-2.23%)
(As of 11/26/2021 04:00 PM ET)
Add
Compare
Today's Range
$0.43
$0.45
50-Day Range
$0.44
$0.79
52-Week Range
$0.42
$5.53
Volume
1.32 million shs
Average Volume
6.31 million shs
Market Capitalization
$68.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.24
30 days | 90 days | 365 days | Advanced Chart
Receive EVFM News and Ratings via Email

Sign-up to receive the latest news and ratings for Evofem Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Evofem Biosciences logo

About Evofem Biosciences

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate) a hormone-free vaginal gel and EVO100 an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.

Headlines

Here's what Wall Street expects from Evofem Biosciences's earnings
November 14, 2021 |  markets.businessinsider.com
Earnings Preview For Evofem Biosciences
November 12, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EVFM
Employees
147
Year Founded
N/A

Sales & Book Value

Annual Sales
$450 thousand
Book Value
($0.38) per share

Profitability

Net Income
$-142.31 million
Net Margins
-4,011.48%
Pretax Margin
-4,011.21%

Debt

Price-To-Earnings

Miscellaneous

Free Float
149,155,000
Market Cap
$68.14 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
11/26/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/03/2022

MarketRank

Overall MarketRank

1.66 out of 5 stars

Medical Sector

973rd out of 1,392 stocks

Pharmaceutical Preparations Industry

459th out of 670 stocks

Analyst Opinion: 3.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Evofem Biosciences (NASDAQ:EVFM) Frequently Asked Questions

Is Evofem Biosciences a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evofem Biosciences in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Evofem Biosciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EVFM, but not buy additional shares or sell existing shares.
View analyst ratings for Evofem Biosciences
or view top-rated stocks.

How has Evofem Biosciences' stock price been impacted by COVID-19 (Coronavirus)?

Evofem Biosciences' stock was trading at $5.16 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EVFM stock has decreased by 91.5% and is now trading at $0.4390.
View which stocks have been most impacted by COVID-19
.

When is Evofem Biosciences' next earnings date?

Evofem Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Evofem Biosciences
.

How were Evofem Biosciences' earnings last quarter?

Evofem Biosciences, Inc. (NASDAQ:EVFM) posted its quarterly earnings data on Monday, November, 15th. The biotechnology company reported ($0.48) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.18. Evofem Biosciences had a negative trailing twelve-month return on equity of 1,593.89% and a negative net margin of 4,011.48%. During the same period in the prior year, the business posted ($0.33) earnings per share.
View Evofem Biosciences' earnings history
.

What price target have analysts set for EVFM?

2 brokers have issued twelve-month price targets for Evofem Biosciences' stock. Their forecasts range from $1.00 to $2.00. On average, they anticipate Evofem Biosciences' stock price to reach $1.50 in the next year. This suggests a possible upside of 241.7% from the stock's current price.
View analysts' price targets for Evofem Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Evofem Biosciences' key executives?

Evofem Biosciences' management team includes the following people:

What other stocks do shareholders of Evofem Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evofem Biosciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), Bionano Genomics (BNGO), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), OrganiGram (OGI), Gran Tierra Energy (GTE), Novan (NOVN) and KushCo (KSHB).

What is Evofem Biosciences' stock symbol?

Evofem Biosciences trades on the NASDAQ under the ticker symbol "EVFM."

Who are Evofem Biosciences' major shareholders?

Evofem Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.49%), Geode Capital Management LLC (0.86%), Fuller & Thaler Asset Management Inc. (0.70%), Millennium Management LLC (0.42%), Morgan Stanley (0.13%) and Tocqueville Asset Management L.P. (0.10%). Company insiders that own Evofem Biosciences stock include Alexander A Fitzpatrick, Anthony Stephen O'brien, Justin J File, Justin J File, Kelly Culwell, Kim P Kamdar, Lisa Dale Rarick, Ltd Invesco, Russell Barrans, Saundra L Pelletier, Saundra L Pelletier and William Walmsley Hall.
View institutional ownership trends for Evofem Biosciences
.

Which major investors are selling Evofem Biosciences stock?

EVFM stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Millennium Management LLC, GSA Capital Partners LLP, Citadel Advisors LLC, Commonwealth Equity Services LLC, Tocqueville Asset Management L.P., and Jane Street Group LLC.
View insider buying and selling activity for Evofem Biosciences
or view top insider-selling stocks.

Which major investors are buying Evofem Biosciences stock?

EVFM stock was acquired by a variety of institutional investors in the last quarter, including Fuller & Thaler Asset Management Inc., BlackRock Inc., Geode Capital Management LLC, Goldman Sachs Group Inc., and UBS Group AG. Company insiders that have bought Evofem Biosciences stock in the last two years include Alexander A Fitzpatrick, Anthony Stephen O'brien, Justin J File, Kim P Kamdar, Lisa Dale Rarick, Ltd Invesco, Russell Barrans, Saundra L Pelletier, and William Walmsley Hall.
View insider buying and selling activity for Evofem Biosciences
or or view top insider-buying stocks.

How do I buy shares of Evofem Biosciences?

Shares of EVFM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evofem Biosciences' stock price today?

One share of EVFM stock can currently be purchased for approximately $0.44.

How much money does Evofem Biosciences make?

Evofem Biosciences has a market capitalization of $68.14 million and generates $450 thousand in revenue each year. The biotechnology company earns $-142.31 million in net income (profit) each year or ($1.81) on an earnings per share basis.

How many employees does Evofem Biosciences have?

Evofem Biosciences employs 147 workers across the globe.

What is Evofem Biosciences' official website?

The official website for Evofem Biosciences is www.evofem.com.

Where are Evofem Biosciences' headquarters?

Evofem Biosciences is headquartered at 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130.

How can I contact Evofem Biosciences?

Evofem Biosciences' mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at (858) 550-1900, via email at [email protected], or via fax at 844-828-2010.


This page was last updated on 11/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.